Siakantaris Marina P, Tsirigotis Panagiotis, Stavroyianni Niki, Argyropoulos Kimon V, Girkas Konstantinos, Pappa Vasiliki, Chondropoulos Spiros, Papadavid Evangelia, Sakellari Ioanna, Anagnostopoulos Achilles, Antoniou Christina, Dervenoulas John
1st Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Greece.
Transfus Apher Sci. 2012 Apr;46(2):189-93. doi: 10.1016/j.transci.2011.10.029. Epub 2011 Dec 16.
Extracorporeal photopheresis (ECP) is an established therapy for cutaneous T-cell lymphoma (CTCL). The objective of this study was to further explore the clinical efficacy of ECP combined with immunomodulatory agents. Eighteen patients with histologically proven CTCL were followed-up after therapy with ECP, mainly combined with interferon-α or bexarotene. A total of 61% of patients responded to therapy (n=11; CR: 5, PR: 6). Median survival was 51 months, progression free survival was 28 months and response duration was 29 ± 23.9 months. ECP combined therapy was highly effective or had a palliative effect in CTCL resistant to previous treatments.
体外光化学疗法（ECP）是一种已确立的皮肤T细胞淋巴瘤（CTCL）治疗方法。本研究的目的是进一步探索ECP联合免疫调节剂的临床疗效。18例经组织学证实的CTCL患者在接受ECP治疗后进行随访，主要联合使用α干扰素或贝沙罗汀。共有61%的患者对治疗有反应（n = 11；完全缓解：5例，部分缓解：6例）。中位生存期为51个月，无进展生存期为28个月，缓解持续时间为29±23.9个月。ECP联合疗法对先前治疗耐药的CTCL具有高效或姑息作用。
